Boston Scientific Corporation (BSX)
Boston Scientific Corporation Revenue Growth: -3.06%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BSX Revenue Growth Rankings
| Overall | 25th percentile | 3272 of 4381 |
| Sector | 25th percentile | 344 of 460 in Healthcare |
| Industry | 22nd percentile | 59 of 76 in Medical Appliances & Equipment |
BSX Revenue Growth Range, Past 5 Years
| Minimum | -7.69% | Dec 2011 |
| Maximum | 4.21% | Dec 2007 |
| Average | -1.76% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these BSX related companies
BSX News
Pre-Open Movers 5/18: (PSUN) (WGO) (CRM) Higher; (ADSK) (SQNM) (ARUN) Lower (more...)
May 18, 9:28AM Street Insider
May 18, 9:28AM Street Insider
Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
May 18, 8:30AM PR Newswire
May 18, 8:30AM PR Newswire
Boston Scientific (BSX) Reports Encouraging Data from PROMUS Element Study;
May 18, 6:52AM Street Insider
May 18, 6:52AM Street Insider
After-Hours Movers 05/17: (PSUN) (OSIR) (CRM) (BSX) Higher; (SQNM) (ARUN) (SIRI) Lower
May 17, 5:40PM Street Insider
May 17, 5:40PM Street Insider
Boston Scientific (BSX) Ticks Higher Following FDA Approval of Stent System
May 17, 5:30PM Street Insider
May 17, 5:30PM Street Insider
$BSX Boston Scientific Announces FDA Approval and U.S. Launch of EPIC Vascular Stent
about 7 days ago by RSInvest
about 7 days ago by RSInvest
Boston Scientific (BSX) Gets FDA Approval for Epic Vascular Self-Expanding Stent System
May 17, 5:16PM Street Insider
May 17, 5:16PM Street Insider
Boston Scientific Announces FDA Approval and U.S. Launch of EPIC Vascular Stent
May 17, 5:16PM Benzinga
May 17, 5:16PM Benzinga
Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
May 17, 5:14PM PR Newswire
May 17, 5:14PM PR Newswire
$STXS raises 18.5M to pay down credit facility and for general corporate purposes http://stks.co/3r3z $JNJ $BSX $HNSN
about 8 days ago by ATandon_STE
about 8 days ago by ATandon_STE
Boston Scientific Announces Positive Data from Lotus Transcatheter Aortic Valve Trial
May 15, 12:46PM Benzinga
May 15, 12:46PM Benzinga
Boston Scientific (BSX) Reports Encouraging Data from REPRISE I Feasibility
May 15, 11:11AM Street Insider
May 15, 11:11AM Street Insider
Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
May 15, 11:00AM Benzinga
May 15, 11:00AM Benzinga
UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific
May 14, 11:33AM Benzinga
May 14, 11:33AM Benzinga
Boston Scientific (BSX), Philips (PHG) Enter Imaging Equipment Sales Agreement
May 14, 8:33AM Street Insider
May 14, 8:33AM Street Insider
I have a $BSX bond maturing in 2035 at 122w 7% coupon. The stock can't get out of its way. Cuckoo! It's called a bubble.
about 22 days ago by frotuss
about 22 days ago by frotuss
$BSX http://stks.co/3Y6W Watching for a break above this downtrend line.
about 28 days ago by jamiemc101
about 28 days ago by jamiemc101
Great to be spot on with $bsx, predicted over 6 ands its already well above. Sold some calls not sure if we see 7 just yet
about 28 days ago by frankdatrader
about 28 days ago by frankdatrader
$EW $BSX 2 players in the same industry both flashing golden cross signals at same time is telling you something. http://stks.co/3XeV
about 28 days ago by tradewithpete
about 28 days ago by tradewithpete
Sold bunch of calls on my $bsx time to take profit again, not sure we r gonna break just yet.
about 30 days ago by frankdatrader
about 30 days ago by frankdatrader
$BSX closing above $6 a big deal. Getting ready to golden cross. Big winner if Obamacare reversed.
about 30 days ago by mattowan
about 30 days ago by mattowan
My God! When did $BSX become a $5 stock? Last time I looked, it was $40 or something. #BadTrader $$
about 32 days ago by Shoofly7
about 32 days ago by Shoofly7
Leerink analyst says $BSX Cognis defibrillator linked to a death, says device risk "relatively minor"
about 32 days ago by Street_Insider
about 32 days ago by Street_Insider
I didn't see anything in the $BSX report that argues for investing in anything to do with medical devices these days.
about 35 days ago by bradloncar
about 35 days ago by bradloncar
Listen to $BSX Q1 2012 earnings call - live at 08:00 AM, ondemand after - http://stks.co/3PVl
about 36 days ago by earningscast
about 36 days ago by earningscast
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BSX | 5.93 | +0.02 | +0.34% | 8.574B |
| BSRR | 8.97 | +0.38 | +4.42% | 121.12M |
| BSI | 2.59 | +0.00 | +0.00% | 170.91M |
| BSET | 9.70 | +0.19 | +2.00% | 107.18M |
| BSD | 14.38 | -0.02 | -0.14% | |
| BRKS | 10.11 | +0.27 | +2.74% | 651.90M |
| BRK.A | 120304 | -150.90 | -0.13% | 198.75B |
| BRE | 50.44 | -0.14 | -0.28% | 3.903B |
| BRCM | 31.25 | -1.04 | -3.22% | 17.60B |
| BRCD | 4.73 | -0.32 | -6.34% | 2.316B |
